Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism

GLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening.

Subsidie
€ 2.495.924
2023

Projectdetails

Introduction

The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET).

Limitations of Current Technology

Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations:

  • PET involves harmful ionizing radiation.
  • PET is expensive and not widely available.
  • PET cannot differentiate between cancer-specific and normal cellular glucose uptake.

These limitations prohibit an even more widespread use of PET, e.g., for screening.

Proposed Solution

We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI), that will overcome these limitations. Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g., targeting Glc metabolism in cancer.

After ingestion, this labeled Glc is metabolized in cells, and the label is transferred to all metabolic products, which can be tracked by DMI.

Research Objectives

Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:

  1. Is DMI a viable alternative for whole-body cancer assessment?
  2. How is DMI positioned compared to Glc-sensitive PET?
  3. Can DMI be performed on widely available MRI systems and simultaneously with standard MRI?

Impact of GLUCO-SCAN

GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high-risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.495.924
Totale projectbegroting€ 2.495.924

Tijdlijn

Startdatum1-12-2023
Einddatum30-11-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • MEDIZINISCHE UNIVERSITAET WIENpenvoerder

Land(en)

Austria

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Revealing liver micrometastases in vivo using ultra-high definition MRI

MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.

€ 1.998.456
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

€ 1.497.669
ERC Proof of...

MAGNIFICO-Pre-commercialization of multifunctional targeted MRI-contrast enhancing agents for brain research

This project aims to enhance MRI's capabilities for brain disease research by developing targeted fluorescent contrast agents and engineering cells for improved in vivo imaging.

€ 150.000
ERC Consolid...

Screening And Future Enhanced MRI

SAFE-MRI seeks to enhance breast cancer detection and MRI performance by implementing abbreviated screening for younger women and reducing contrast use through advanced imaging techniques.

€ 2.984.796
ERC Starting...

Introducing deuterium for next generation chemical biology probes and direct imaging

This project aims to revolutionize microscopy by using deuterated compounds for super-resolution imaging and drug tracking in live cells, enhancing protein localization and neural signaling without genetic modifications.

€ 1.499.469

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

DDG-MRI for cancer detection - A novel medical imaging approach that correlates to FDG-PET without ionising radiation

The DDG-MRI project aims to develop a non-ionizing MRI technique using a novel deuterated glucose analogue to provide PET-like imaging for cancer detection and treatment monitoring.

€ 2.991.061
EIC Transition

MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care

MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.

€ 2.495.127
EIC Pathfinder

REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION

RETIMAGER aims to revolutionize PET imaging by achieving ten-fold improvements in spatial and temporal resolution, enabling real-time, high-sensitivity imaging for personalized precision medicine.

€ 3.126.347
EIC Transition

Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions

MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.

€ 2.100.238
EIC Transition

Early detection of treatment response in breast cancer

The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.

€ 2.499.229